Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering

WARRINGTON, Pa. , April 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced the pricing of its underwritten public offering